Nadene Henderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nadene Henderson has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Can Ficicioglu
Section of Biochemical Genetics, Division of Genetics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
2 shared publications - Damara Ortiz
UPMC Children's Hospital of Pittsburgh, 4401 Penn Avenue, Pittsburgh, PA 15224, USA
2 shared publications - Ashley Lahr
UPMC Children's Hospital of Pittsburgh, 4401 Penn Avenue, Pittsburgh, PA 15224, USA
1 shared publication - Brenda S. DiBoscio
Division of Human Genetics/Metabolism, Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA
1 shared publication - Caitlin Menello
Section of Biochemical Genetics, Division of Genetics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
1 shared publication - Carlos Enrique Prada
Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL
1 shared publication
Latest Publications
- Open Access
- 25 September 2023
- Published by LIDSEN Publishing Inc in OBM Genetics
- Vol. 07 (03) , 1-12
Overview of Newborn Screening of Lysosomal Storage Diseases for Pediatric Care Providers
Lysosomal storage disorders (LSD) are caused by enzymatic failure to degrade specific cellular byproducts of metabolism within the lysosome. They have a wide range of presentations involving multiple body systems and can manifest from infancy through adulthood. As treatments have become available for many of these disorders, newborn screening has been adapted for early identification and pre-symptomatic treatment. This article will review some of the LSD that are now being added to newborn screening panels, including globoid cell leukodystrophy (Krabbe), Gaucher disease, Fabry disease, Mucopolysaccharidosis Type I (Hurler; MPSI), Mucopolysaccharidosis Type II (Hunter; MPSII), Acid Sphingomyelinase deficiency (ASMD), and Pompe disease.
- 25 September 2023
- Published by LIDSEN Publishing Inc in OBM Genetics
- Vol. 07 (03) , 1-12
Open AccessOverview of Newborn Screening of Lysosomal Storage Diseases for Pediatric Care Providers
Lysosomal storage disorders (LSD) are caused by enzymatic failure to degrade specific cellular byproducts of metabolism within the lysosome. They have a wide range of presentations involving multiple body systems and can manifest from infancy through adulthood. As treatments have become available for many of these disorders, newborn screening has been adapted for early identification and pre-symptomatic treatment. This article will review some of the LSD that are now being added to newborn screening panels, including globoid cell leukodystrophy (Krabbe), Gaucher disease, Fabry disease, Mucopolysaccharidosis Type I (Hurler; MPSI), Mucopolysaccharidosis Type II (Hunter; MPSII), Acid Sphingomyelinase deficiency (ASMD), and Pompe disease.
- Open Access
- 9 March 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 136 (1) , 4-21
The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?
- 9 March 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 136 (1) , 4-21
Open AccessThe diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?
- Open Access
- 13 November 2020
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (4) , 89
Newborn Screening for Pompe Disease: Pennsylvania Experience
Pennsylvania started newborn screening for Pompe disease in February 2016. Between February 2016 and December 2019, 531,139 newborns were screened. Alpha-Glucosidase (GAA) enzyme activity is measured by flow-injection tandem mass spectrometry (FIA/MS/MS) and full sequencing of the GAA gene is performed as a second-tier test in all newborns with low GAA enzyme activity [<2.10 micromole/L/h]. A total of 115 newborns had low GAA enzyme activity and abnormal genetic testing and were referred to metabolic centers. Two newborns were diagnosed with Infantile Onset Pompe Disease (IOPD), and 31 newborns were confirmed to have Late Onset Pompe Disease (LOPD). The incidence of IOPD + LOPD was 1:16,095. A total of 30 patients were compound heterozygous for one pathogenic and one variant of unknown significance (VUS) mutation or two VUS mutations and were defined as suspected LOPD. The incidence of IOPD + LOPD + suspected LOPD was 1: 8431 in PA. We also found 35 carriers, 15 pseudodeficiency carriers, and 2 false positive newborns.
- 13 November 2020
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (4) , 89
Open AccessNewborn Screening for Pompe Disease: Pennsylvania Experience
Pennsylvania started newborn screening for Pompe disease in February 2016. Between February 2016 and December 2019, 531,139 newborns were screened. Alpha-Glucosidase (GAA) enzyme activity is measured by flow-injection tandem mass spectrometry (FIA/MS/MS) and full sequencing of the GAA gene is performed as a second-tier test in all newborns with low GAA enzyme activity [<2.10 micromole/L/h]. A total of 115 newborns had low GAA enzyme activity and abnormal genetic testing and were referred to metabolic centers. Two newborns were diagnosed with Infantile Onset Pompe Disease (IOPD), and 31 newborns were confirmed to have Late Onset Pompe Disease (LOPD). The incidence of IOPD + LOPD was 1:16,095. A total of 30 patients were compound heterozygous for one pathogenic and one variant of unknown significance (VUS) mutation or two VUS mutations and were defined as suspected LOPD. The incidence of IOPD + LOPD + suspected LOPD was 1: 8431 in PA. We also found 35 carriers, 15 pseudodeficiency carriers, and 2 false positive newborns.
- Open Access
- 3 September 2020
- Published by Wiley in Journal of Genetic Counseling
- Vol. 29 (5) , 715-717
Fabry Disease practice resource: Focused revision
- 3 September 2020
- Published by Wiley in Journal of Genetic Counseling
- Vol. 29 (5) , 715-717
Open AccessFabry Disease practice resource: Focused revision